Linked Life Data

16153200

Source:http://linkedlifedata.com/resource/pubmed/id/16153200

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2005-9-12
pubmed:abstractText
To evaluate the activity of nilutamide as secondary hormonal therapy in patients with androgen-independent prostate cancer (AIPC), as treatment options are limited for these patients and secondary hormonal therapy with antiandrogens has advantages, including low toxicity, oral administration and high patient acceptance.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1464-4096
pubmed:author
pubmed:issnType
Print
pubmed:volume
96
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
783-6
pubmed:dateRevised
2006-7-18
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer.
pubmed:affiliation
Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Haber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
pubmed:publicationType
Journal Article, Multicenter Study